

BENTLEY PHARMACEUTICALS INC  
Form 8-K  
November 03, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**November 2, 2005**

Date of Report (Date of Earliest Event Reported)

**BENTLEY PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**1-10581**

(Commission File Number)

**59-1513162**

(I.R.S. Employer Identification No.)

**Bentley Park  
2 Holland Way**

**Exeter, New Hampshire**  
(Address of Principal Executive Offices)

**03833**

(Zip Code)

**(603) 658-6100**

(Registrant's Telephone Number, Including Area Code)

Edgar Filing: BENTLEY PHARMACEUTICALS INC - Form 8-K

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02. Results of Operations and Financial Condition.**

On November 2, 2005, Bentley Pharmaceuticals, Inc. issued a press release announcing financial results for the three and nine months ended September 30, 2005. A copy of the press release is furnished herewith as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits

99.1 Earnings press release for the three and nine months ended September 30, 2005 dated November 2, 2005.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2005

By: /s/ Michael D. Price  
Michael D. Price  
Vice President and  
Chief Financial Officer

**BENTLEY PHARMACEUTICALS, INC.**

**EXHIBIT INDEX**

**Exhibit  
Number**

**Description of Exhibit**

99.1 Earnings press release for the three and nine months ended September 30, 2005 dated November 2, 2005.